Aclaris Therapeutics, Inc.
0H8T.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$534.91M
Close$
$-0.85
125.1% downside
Current Fair Value
125.1% downsideOvervalued by 125.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $534.91 Million |
|---|---|
| Enterprise Value | $519.72 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.78 |
| Outstanding Shares | 142,736,848 |
Return
| Return on Equity | -60.79% |
|---|---|
| Return on Assets | -42.15% |
| Return on Invested Capital | -53.25% |
Valuation & Multiples
| P/E Ratio | -6.6 |
|---|---|
| PEG | -16.77 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 63.23 |
| Enterprise Value to EBIT | -6.44 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$1.38 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$1.30 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aclaris Therapeutics Inc
73 employees
CEO: Neal Walker Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in the United States, dedicated to discovering and advancing novel therapeutic agents for immune-inflammatory diseases. The company operates through two distinct...